$VRSK

Verisk (NASDAQ: VRSK) officer to sell 7,821 shares in 2026

Verisk (VRSK) officer Nicholas Daffan plans to sell 7,821 shares, valued at $1.49M, in 2026. The sale follows the exercise of employee stock options and will be broker-assisted. Verisk has 130.16M shares outstanding.

Original reporting
Published Aug 27, 2026, 8:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$VRSK
Neutral
high confidence
Mentioned
$VRSK
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

The disclosed sale adds a modest amount of shares to the market, but given Verisk's large float, the impact is expected to be negligible.

02

Market read

Routine insider sale with limited price impact; primarily of interest to short-term traders monitoring insider activity.

03

What to watch

Potential cumulative effect if multiple insiders sell around the same time.

Relevance 4/10Novelty 4/10Timing: proposed sale date 08/27/2026

Background

Rule 144 filings allow insiders to sell restricted shares after meeting holding periods, often viewed as a liquidity event.

Company-level read

Ticker impact

$VRSKNeutralHigh confidence
Context

Officer Nicholas Daffan filed a Rule 144 notice to sell 7,821 Verisk shares valued at $1.49 M on 08/27/2026.

Expected impact

Minimal downward pressure; unlikely to move price materially.

Evidence & confidence

The sale size is small relative to float and market cap; typical for routine insider liquidity events.

Market effects

None; Verisk operates in data analytics, a single insider sale does not affect sector trends.

None; the filing is U.S.-focused and limited to one company.

Low; no broader market impact.

Counterpoint

If the insider is signaling lack of confidence, a short position could be considered despite the small size.

Key entities

  • Verisk Analytics, Inc.

    Provider of data analytics and risk assessment solutions.

  • Nicholas Daffan

    Verisk officer filing the Rule 144 notice.

Related articles

$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer

$VRSKMed

Verisk Told It Can't Abandon $2.35B AccuLynx Deal

Delaware Chancery Court ruled that Verisk Analytics Inc. improperly exited its $2.35 billion acquisition of AccuLynx, according to the court. The decision requires Verisk to proceed with the deal, affecting the timing and terms of the insurance data and software transaction for investors.

$VRSKMed

Why is Verisk Analytics stock sliding today?

Verisk Analytics shares fell 5.6% after the Delaware Chancery Court ruled Verisk must proceed with its $2.35 billion AccuLynx acquisition. The court said Verisk’s conduct invalidated its Dec 2025 deal termination and awarded AccuLynx damages plus interest. Verisk said it strongly disagrees and is evaluating next steps, including a possible appeal, while FTC antitrust review remains unresolved.

$VRSKMedAI 8/10

Verisk stock falls after court rejects $2.35B merger termination

Verisk Analytics (NASDAQ:VRSK) shares fell about 5.5% after a Delaware Chancery Court rejected Verisk’s bid to terminate its $2.35B acquisition of AccuLynx. The court said Verisk’s termination was invalid and AccuLynx is owed damages for direct costs plus interest. Verisk said it strongly disagrees and is evaluating options, including an appeal.

$VRSKMedAI 8/10

Verisk Slides as Court Revives AccuLynx Deal Fight

Verisk Analytics (VRSK) fell about 5% as a Delaware Court of Chancery ruling revived its dispute over the terminated AccuLynx acquisition. Verisk agreed to buy AccuLynx in July 2025 and terminated in Dec. 2025. The court required Verisk to pursue regulatory approval efforts for the $2.35 billion deal. Verisk reported Q2 2026 revenue of $806 million.